Table 1.
Demographic and oncological data of patients that underwent a RAMIE procedure with and without the ESOMAP protocol.
| ESOMAP | RAMIE | ||
|---|---|---|---|
| Total (%) | Total (%) | p Value | |
| Patients | 20 (100) | 86 (100) | - |
| Male | 17 (85) | 71 (82.6) | 1 |
| Adenocarcinoma | 19 (95) | 66 (76.7) | 0.1150 |
| Squamous Cell Carcinoma | 1 (5) | 19 (22.1) | 0.1127 |
| Other | 0 | 1 (1.2) | 1 |
| Neoadjuvant Therapy | |||
| None | 1 (5) | 17 (19.8) | 0.1849 |
| CROSS | 12 (60) | 38 (44.2) | 0.2234 |
| FLOT | 7 (35) | 30 (34.9) | 1 |
| Other | 0 | 1 (1.2) | 1 |
| Pathological Tumor Stage | |||
| T0 | 3 (15) | 14 (16.3) | 1 |
| T1a | 2 (10) | 7 (8.1) | 0.6768 |
| T1b | 4 (20) | 12 (14) | 0.4971 |
| T2 | 4 (20) | 11 (12.8) | 0.4761 |
| T3 | 7 (35) | 37 (43) | 0.6179 |
| T4 | 0 | 4 (4.7) | 1 |
| Tx | 0 | 1 (1.2) | 1 |
| Pathological Nodal Stage | |||
| N0 | 14 (70) | 48 (55.8) | 0.3170 |
| N1 | 2 (10) | 17 (19.8) | 0.5174 |
| N2 | 3 (15) | 10 (11.6) | 0.7079 |
| N3 | 1 (5) | 11 (12.8) | 0.4561 |